Journal
JOURNAL OF CLINICAL IMMUNOLOGY
Volume 32, Issue 5, Pages 1059-1070Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10875-012-9689-9
Keywords
Adoptive immunotherapy; chimeric antigen receptor; dual; specificity; targeting; MUC1; ErbB2
Categories
Funding
- Breast Cancer Campaign Project Grant [2006NovPR18]
- Guy's and St Thomas' Charity
- Experimental Cancer Medicine Centre (King's College London)
- Guy's via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre (BRC)
- King's College London
- King's College Hospital NHS Foundation Trust
- Oracle Cancer Trust at the Royal Marsden Hospital
- Institute of Cancer Research (ICR)
- Cancer Research UK [CA309/A8274]
- NIHR
- ICR
- Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre (BRC)
- Academy of Medical Sciences (AMS) [AMS-SGCL6-Papa] Funding Source: researchfish
- Cancer Research UK [11566] Funding Source: researchfish
- National Institute for Health Research [CL-2011-17-007] Funding Source: researchfish
Ask authors/readers for more resources
Chimeric antigen receptor (CAR) engineered T-cells occupy an increasing niche in cancer immunotherapy. In this context, CAR-mediated CD3 zeta signaling is sufficient to elicit cytotoxicity and interferon-gamma production while the additional provision of CD28-mediated signal 2 promotes T-cell proliferation and interleukin (IL)-2 production. This compartmentalisation of signaling opens the possibility that complementary CARs could be used to focus T-cell activation within the tumor microenvironment. Here, we have tested this principle by co-expressing an ErbB2- and MUC1-specific CAR that signal using CD3 zeta and CD28 respectively. Stoichiometric co-expression of transgenes was achieved using the SFG retroviral vector containing an intervening Thosea asigna peptide. We found that dual-targeted T-cells kill ErbB2(+) tumor cells efficiently and proliferate in a manner that requires co-expression of MUC1 and ErbB2 by target cells. Notably, however, IL-2 production was modest when compared to control CAR-engineered T-cells in which signaling is delivered by a fused CD28 + CD3 zeta endodomain. These findings demonstrate the principle that dual targeting may be achieved using genetically targeted T-cells and pave the way for testing of this strategy in vivo.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available